Clinical trial
Taxoprexin® Treatment for Advanced Eye Melanoma
NCT00244816 · American Regent, Inc., Industry · Completed
Key facts
| NCT number | NCT00244816 |
|---|---|
| Title | Taxoprexin® Treatment for Advanced Eye Melanoma |
| Official title | Phase II Open-Label Study of Weekly Taxoprexin® (DHA-paclitaxel) Injection as Treatment of Patients With Metastatic Uveal (Choroidal) Malignant Melanoma |
| Lead sponsor | American Regent, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Melanoma |
| Intervention type | Drug |
| Interventions | Taxoprexin |
| Enrollment | 22 |
| Start date | Oct 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Oct 27, 2005 |
| Last update posted | Oct 23, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: